APA (7th ed.) Citation

Musto, F., Stracuzzi, M., Cibarelli, A., Coppola, C., Caiazzo, R., David, D., . . . Giacomet, V. (2025). Real-Life Efficacy and Safety of Glecaprevir/Pibrentasvir Pediatric Formulation for Chronic Hepatitis C Infection in Children Aged 3 to 12 Years: A Case Series of 6 Patients. Clinical therapeutics, 47(3), 244-247. https://doi.org/10.1016/j.clinthera.2024.12.011

Chicago Style (17th ed.) Citation

Musto, Francesca, et al. "Real-Life Efficacy and Safety of Glecaprevir/Pibrentasvir Pediatric Formulation for Chronic Hepatitis C Infection in Children Aged 3 to 12 Years: A Case Series of 6 Patients." Clinical Therapeutics 47, no. 3 (2025): 244-247. https://doi.org/10.1016/j.clinthera.2024.12.011.

MLA (9th ed.) Citation

Musto, Francesca, et al. "Real-Life Efficacy and Safety of Glecaprevir/Pibrentasvir Pediatric Formulation for Chronic Hepatitis C Infection in Children Aged 3 to 12 Years: A Case Series of 6 Patients." Clinical Therapeutics, vol. 47, no. 3, 2025, pp. 244-247, https://doi.org/10.1016/j.clinthera.2024.12.011.